Zobrazeno 1 - 3
of 3
pro vyhledávání: '"Aliyah Pabani, MD"'
Autor:
Daniel E. Meyers, MD, MSc, Meghann Pasternak, MD, MSc, Samantha Dolter, MD, Heidi A.I. Grosjean, MD, Chloe A. Lim, MD, Igor Stukalin, MD, Siddhartha Goutam, MD, Vishal Navani, M.B.B.S., MRCP, Daniel Y.C. Heng, MD, MPH, Winson Y. Cheung, MD, PhD, Don G. Morris, MD, PhD, Aliyah Pabani, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 4, Pp 100482- (2023)
Introduction: Landmark trials testing immune checkpoint inhibitors (ICIs) in advanced NSCLC are difficult to extrapolate to real-world practice given the exclusion of patients with poor (i.e., ≥2) Eastern Cooperative Oncology Group performance stat
Externí odkaz:
https://doaj.org/article/60af4c1049ba410eb0ed27eb16724e8a
Autor:
Amanda J.W. Gibson, BSc (Hons), Aliyah Pabani, MD, Michelle L. Dean, BSc, Guillermo Martos, MD, Winson Y. Cheung, MD, MPH, FRCPC, Vishal Navani, M.B.B.S., MRCP, FRACP
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 3, Pp 100460- (2023)
Introduction: BRAF mutations (present in 2%–3% of NSCLC) are a known oncogenic driver and emerging therapeutic target. There is a scarcity of real-world data describing the clinical characteristics, treatment patterns, and effectiveness of targeted
Externí odkaz:
https://doaj.org/article/e78d94bf195a4c678af18447c01445fa
Autor:
Anifat A. Elegbede, MSc, MbChB, Amanda J. Gibson, BSc, Andrea S. Fung, PhD, MD, Winson Y. Cheung, MD, MPH, Michelle L. Dean, BSc, D. Gwyn Bebb, BMBCh, PhD, Aliyah Pabani, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 12, Pp 100249- (2021)
Introduction: The real-world data evaluating treatment outcomes of atezolizumab plus carboplatin-etoposide chemotherapy (atezolizumab) for extensive-stage SCLC (ESCLC) are lacking. Our objective was to evaluate real-world outcomes of ESCLC treated wi
Externí odkaz:
https://doaj.org/article/6d9518960e1846f9a1d2a211e151b458